Although the PL1-OX40 + anti-OX40 Ab treatments significantly decreased B16F10 tumor growth and prolonged survival (Supplementary Fig. 9a–c), complete eradication of the tumor burden is an important goal of immune-based treatments. This evidence concerns the gene TNFRSF4 and neoplasm.